Market revenue in 2023 | USD 22.3 million |
Market revenue in 2030 | USD 55.0 million |
Growth rate | 13.8% (CAGR from 2023 to 2030) |
Largest segment | Kallikrein inhibitor |
Fastest growing segment | Kallikrein inhibitor |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.84% in 2023. Horizon Databook has segmented the UAE hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
The UAE's hereditary angioedema therapeutics market is anticipated to witness significant growth over the forecast period, owing to various factors such as an increasing number of strategic initiatives undertaken by local players and a growing number of government initiatives.
Key players operating in the market are focusing on drug approval to meet the rising demand for therapeutics. For instance, in July 2020, the UAE Ministry of Health and Prevention approved the use of Lanadelumab, a subcutaneous injection for patients suffering from HAE.
Moreover, in September 2021, BioCryst Pharmaceuticals, Inc. announced the approval of Orladeyo (berotralstat), a formulation used for the prophylaxis of HAE among patients aged 12 years and above. These factors are driving the market growth in the region. However, the lack of proper diagnostics that help manage the condition effectively is anticipated to hamper market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into UAE hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account